Principal Financial Group Inc. reduced its position in shares of TESARO, Inc. (NASDAQ:TSRO) by 0.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,834 shares of the biopharmaceutical company’s stock after selling 198 shares during the period. Principal Financial Group Inc. owned 0.06% of TESARO worth $5,206,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in TSRO. Bank of New York Mellon Corp raised its position in TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock worth $103,954,000 after buying an additional 175,273 shares in the last quarter. Macquarie Group Ltd. raised its position in TESARO by 4.8% in the fourth quarter. Macquarie Group Ltd. now owns 301,510 shares of the biopharmaceutical company’s stock worth $40,547,000 after buying an additional 13,830 shares in the last quarter. Norges Bank purchased a new position in TESARO during the fourth quarter worth approximately $40,158,000. Pictet Asset Management Ltd. raised its position in TESARO by 8.1% in the first quarter. Pictet Asset Management Ltd. now owns 286,236 shares of the biopharmaceutical company’s stock worth $44,043,000 after buying an additional 21,337 shares in the last quarter. Finally, Neuberger Berman Group LLC raised its position in TESARO by 81.0% in the first quarter. Neuberger Berman Group LLC now owns 191,040 shares of the biopharmaceutical company’s stock worth $29,395,000 after buying an additional 85,500 shares in the last quarter.
Shares of TESARO, Inc. (NASDAQ:TSRO) opened at 126.17 on Monday. The firm’s market cap is $6.80 billion. The firm’s 50-day moving average is $146.21 and its 200-day moving average is $151.73. TESARO, Inc. has a 1-year low of $83.26 and a 1-year high of $192.94.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing the consensus estimate of ($2.26) by $0.29. The firm had revenue of $3.10 million for the quarter, compared to the consensus estimate of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The firm’s quarterly revenue was up 909.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.22) EPS. On average, analysts anticipate that TESARO, Inc. will post ($8.75) EPS for the current fiscal year.
TSRO has been the topic of a number of recent analyst reports. Piper Jaffray Companies started coverage on shares of TESARO in a research report on Wednesday, April 12th. They issued an “overweight” rating and a $180.00 price target on the stock. Cowen and Company reaffirmed a “market perform” rating and set a $145.00 target price on shares of TESARO in a research report on Tuesday, March 28th. Cann reaffirmed a “buy” rating and set a $199.00 target price on shares of TESARO in a research report on Monday, June 5th. FBR & Co reaffirmed a “hold” rating on shares of TESARO in a research report on Monday, April 3rd. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $216.00 target price (down previously from $232.00) on shares of TESARO in a research report on Saturday, April 22nd. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $173.74.
In other TESARO news, VP Edward C. English sold 8,500 shares of the stock in a transaction on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares in the company, valued at approximately $748,155.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 34.60% of the stock is owned by company insiders.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.